European Investor
20 Nov 2026, 18:24
Johnson & Johnson Says Tremfya Improves Axial PsA Symptoms and MRI-Confirmed Inflammation
Johnson & Johnson (NYSE: JNJ) reported positive Phase 4 STAR study results for Tremfya in biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial involvement. The study met its primary and major secondary endpoints, showing significant improvement in axial symptoms and reductions in sacroiliac joint inflammation versus placebo.
At Week 24, BASDAI scores improved by 3.3 points with Tremfya every four weeks and 2.9 points with every-eight-week dosing, compared with 2.1 points for placebo. Tremfya also produced greater improvement on ASDAS-CRP, another measure of axial disease activity.
MRI results were particularly notable. Sacroiliac joint inflammation scores fell by 7.1 points with every-four-week dosing and 5.2 points with every-eight-week dosing, versus a 2.4-point reduction with placebo, representing more than twice the improvement seen with placebo. No new safety signals were identified.
The results strengthen Tremfya’s clinical profile in psoriatic arthritis by adding prospective MRI-based evidence in axial disease, an area with limited dedicated trial data. The findings could support broader physician confidence in the drug’s use across different PsA manifestations, although the every-four-week regimen evaluated in the study is not currently approved in the U.S.
Johnson & Johnson (NYSE: JNJ) reported positive Phase 4 STAR study results for Tremfya in biologic-naïve adults with active psoriatic arthritis and MRI-confirmed axial involvement. The study met its primary and major secondary endpoints, showing significant improvement in axial symptoms and reductions in sacroiliac joint inflammation versus placebo.
At Week 24, BASDAI scores improved by 3.3 points with Tremfya every four weeks and 2.9 points with every-eight-week dosing, compared with 2.1 points for placebo. Tremfya also produced greater improvement on ASDAS-CRP, another measure of axial disease activity.
MRI results were particularly notable. Sacroiliac joint inflammation scores fell by 7.1 points with every-four-week dosing and 5.2 points with every-eight-week dosing, versus a 2.4-point reduction with placebo, representing more than twice the improvement seen with placebo. No new safety signals were identified.
The results strengthen Tremfya’s clinical profile in psoriatic arthritis by adding prospective MRI-based evidence in axial disease, an area with limited dedicated trial data. The findings could support broader physician confidence in the drug’s use across different PsA manifestations, although the every-four-week regimen evaluated in the study is not currently approved in the U.S.